ArticleProbiotics and antimicrobial proteins2026
Targeting Pathogenic Infection and Virulence Genes of Enterococcus Faecalis Using Lactoferrin Bismuth Nano-form.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterococcus faecalis (E. faecalis) is an opportunistic pathogen associated with severe infections, particularly in hospital settings. Increasing antibiotic resistance and diverse virulence factors highlights the urgent need for innovative, effective therapeutic approaches. In this study, a lactoferrin-Bismuth Nanoform (LF-Bi-NF) was synthesized and comprehensively characterized using UV-visible spectroscopy, scanning electron microscopy (SEM), energy-dispersive X-ray (EDX) mapping, dynamic light scattering (DLS), and Fourier-transform infrared (FTIR) spectroscopy. However, gamma radiation negatively impacted the stability of LF-Bi-NF. The LF-Bi-NF was evaluated against pathogenic E. faecalis isolates through in vitro assays, in addition to in vivo investigations E. faecalis infected mice. The LF-Bi-NF exhibited antibacterial activity, with inhibition zones of 20.0 ± 0.10, 21.0 ± 0.15, 18.0 ± 0.25, and 15.0 ± 0.31 mm against E. faecalis_1, E. faecalis_2, E. faecalis_3, and E. faecalis ATCC 29212, respectively. While both lactoferrin and bismuth salts alone exhibited no detectable activity. The LF-Bi-NF demonstrated minimum inhibitory concentrations (MICs) of 3.125, 1.56, 6.25, and 12.5 µg/mL and minimum bactericidal concentrations (MBCs) of 12.50, 3.125, 25, and 25 µg/mL against the respective isolates, along with inhibition of biofilm formation at sub-MIC levels. Mechanistic investigations indicated disruption of cell wall integrity, increased membrane permeability, and protein leakage, particularly in the strong biofilm-forming isolate E. faecalis_2. Additionally, gene expression analysis showed that the antibiotic resistance-associated genes norA and ermC and the virulence-associated gene EF3314 were downregulated by 64%, 59%, and 87%, respectively. In vivo studies demonstrated that LF-Bi-NF treatment promoted recovery in infected mice, improved immunological biomarkers (IL-12, IL-10, MPO, and IFN-γ), and significantly reduced bacterial burden in the bloodstream to undetectable levels within four days. In conclusion, LF-Bi-NF represents a promising nano-therapeutic candidate for the treatment of E. faecalis infections, exhibiting strong antibacterial, anti-biofilm, anti-virulence, and immunomodulatory properties.
Indexed as
Identifiers
42262445What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.